SKLB1028, Daunorubicin, and Cytarabine in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia (AML)

Korábbi kezelés

• AML secondary to radiotherapy or chemotherapy for other tumors;
• Major surgery of major organs has been performed before entering the study (for the definition of major surgery, refer to Grade 3 and 4 surgery specified in Management Measures for Clinical Application of Medical Technology, or the patient has not yet fully recovered from
• Subject has received prior therapy for AML with the following exceptions: a. emergency leukapheresis; b. emergency treatment with hydroxyurea ;c. growth factor or cytokine support; d. steroid for anaphylaxis or transfusion reaction;

Más betegség

• Diagnosis of active malignancy other than AML;
• Previous history of other malignancies.
• Patients with clinically significant coagulation abnormalities, such as disseminated intravascular coagulation (DIC), hemophilia A, hemophilia B, and von Willebrand disease;

Egyéb

• Confirmed diagnosis of acute promyelocytic leukemia (M3 /APL), or BCR-ABL positive leukemia (ie, blast crisis of chronic myelogenous leukemia);
• AML with central nervous system involvement;
• Refractory hypokalemia or hypomagnesemia that is not easily corrected by symptomatic treatment and that occurs repeatedly in the past;
• Current clinically significant graft-ve

• Subject has a diagnosis of previously-untreated de novo acute myeloid leukemia (AML) \> 20% blasts in the bone marrow according to WHO classification (2016) documented prior to enrollment.;
• Age ≥ 18 and \< 60 years;
• Subjects who are positive for FLT3 mutations by central laboratory;
• Subject has an Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2;
• Subject must meet the following criteria as indicated on the clinical laboratory tests;
  • Serum aspartate aminotransf
  • Total serum bilirubin ≤ 2.5 x institutional ULN
  • Serum creatinine ≤ 3 x institutional ULN or an estimated glomerular filtration rate (eGFR) of \> 30 ml/min
• Subject is suitable for oral administration of study drug.